Literature DB >> 22341983

[Hypothalamic hamartoma in paediatric patients: clinical characteristics, outcomes and review of the literature].

C Castaño De La Mota1, F Martín Del Valle, A Pérez Villena, M L Calleja Gero, R Losada Del Pozo, M L Ruiz-Falcó Rojas.   

Abstract

OBJECTIVE: To describe the epidemiological and clinical-electroencephalographic characteristics, and associated morbidity of patients with hypothalamic hamartoma, as well as the treatment followed and outcomes PATIENTS AND METHODS: We have retrospectively reviewed the medical histories of 10 patients diagnosed with hypothalamic hamartoma by magnetic resonance imaging over the last 20 years.
RESULTS: The age of onset of epilepsy in patients with hypothalamic hamartoma in our series was between the first days of life and 2 years. Of the 10 total patients, 8 had epileptic seizures during its progress. All of them had gelastic seizures, in addition to other types of seizures, with the most common being partial simple seizures. The electroencephalographic findings recorded were highly variable. One of the patients developed epileptic encephalopathy. Five patients had some kind of conduct disorder. Five patients had cognitive problems. At least 2 different antiepileptic drugs were measured in 8 of the patients who had seizures, and in 6 of these some type of non-pharmacological treatment had been used with the objective of seizure control. Only in 3 of 8 patients has been achieved Acceptable control of epilepsy had only been achieved in 3 out the 8 patients. Five patients of the series developed precocious puberty. The average time of follow-up of the series was approximately 6 years.
CONCLUSIONS: Epilepsy is the most frequent manifestation of hypothalamic hamartomas. Most cases were drug-resistant, which led to difficulties in the management of these patients, requiring surgery for their control on many occasions. Psychiatric comorbidity and cognitive impairment is common.
Copyright © 2011 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22341983     DOI: 10.1016/j.nrl.2011.12.008

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  7 in total

Review 1.  Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity.

Authors:  Victor S Harrison; Oliver Oatman; John F Kerrigan
Journal:  Epilepsia       Date:  2017-06       Impact factor: 5.864

2.  Brief Behavioral Intervention for Disruptive Behavior in a Child with a Hypothalamic Hamartoma: A Case Report.

Authors:  Rachel H Fein; Gabrielle G Banks; Marsha N Gragert; Marni E Axelrad
Journal:  J Clin Psychol Med Settings       Date:  2019-12

3.  Gelastic epilepsy in combination with hypothalamic hamartoma and partial agenesis of the corpus callosum: A case report and review of the literature.

Authors:  Bochao Cheng; Chongran Sun; Shiguang Li; Qiyong Gong; Su Lui
Journal:  Exp Ther Med       Date:  2013-10-08       Impact factor: 2.447

4.  An Undiagnosed Case of Hypothalamic Hamartoma with a Rare Presentation.

Authors:  Shervin Badihian; Saeideh Bahrani; Nasim Tabrizi; Houshang Moein; Mohammad Zare; Majid Barekatain; Reza Basiratnia; Elham Rahimian; Amirali Mehvari Habibabadi; Payam Moein; Jafar Mehvari Habibabadi
Journal:  Case Rep Med       Date:  2017-01-26

5.  Incidental pineal gland cyst in girls with early onset of puberty.

Authors:  Gianpaolo De Filippo; Rossella Gaudino; Valeria Calcaterra; Alberto Villani; Elena Bozzola; Mauro Bozzola
Journal:  Ital J Pediatr       Date:  2022-03-21       Impact factor: 2.638

6.  A Case Report of Dacrystic Seizures in the Psychiatric Emergency Services Department.

Authors:  José C Medina; Roxana Galván; César Y Garfias; Diana J Arteaga
Journal:  Cureus       Date:  2022-03-29

7.  MR imaging of hypothalamic hamartoma in a patient with gelastic seizures.

Authors:  Wan Ahmad Firdaus Wan Chek; Yong Guang Teh; Dian Noriza Eddy Suryono; Chiak Yot Ng; Selim Ahmed
Journal:  Radiol Case Rep       Date:  2021-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.